{"id":"azacitidine-and-eltrombopag","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Azacitidine's mechanism of action involves the inhibition of DNA methyltransferase enzymes, which are responsible for adding methyl groups to DNA, leading to gene silencing. By inhibiting these enzymes, azacitidine increases the expression of tumor suppressor genes, which helps to slow down cancer cell growth. Eltrombopag, on the other hand, works by binding to the thrombopoietin receptor, stimulating platelet production and increasing platelet counts in patients with thrombocytopenia.","oneSentence":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes. Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:17.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of myelodysplastic syndromes (MDS), Treatment of low platelet count (thrombocytopenia) in patients with chronic liver disease"}]},"trialDetails":[{"nctId":"NCT05907499","phase":"PHASE3","title":"Decitabine for Poor Graft Function Post Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-07-01","conditions":"Poor Graft Function","enrollment":76},{"nctId":"NCT02010645","phase":"PHASE2","title":"Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-03","conditions":"Leukemia","enrollment":6},{"nctId":"NCT02158936","phase":"PHASE3","title":"A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-06-10","conditions":"Thrombocytopaenia","enrollment":356},{"nctId":"NCT01488565","phase":"PHASE2","title":"A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2010-12","conditions":"Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML)","enrollment":25},{"nctId":"NCT01481220","phase":"PHASE1","title":"Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Nordic MDS Group","startDate":"2011-10","conditions":"Myelodysplastic Syndrome, Thrombocytopenia","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vidaza (azacitidine)","Revolade (eltrombopag)"],"phase":"phase_2","status":"active","brandName":"Azacitidine and eltrombopag","genericName":"Azacitidine and eltrombopag","companyName":"Peter MacCallum Cancer Centre, Australia","companyId":"peter-maccallum-cancer-centre-australia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes. Eltrombopag is a thrombopoietin receptor agonist that stimulates platelet production. Used for Treatment of myelodysplastic syndromes (MDS), Treatment of low platelet count (thrombocytopenia) in patients with chronic liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}